Chase Sun(SZ:300026) Xin Lang Cai Jing·2025-10-29 01:34Core Insights - Hongri Pharmaceutical (300026.SZ) reported a total operating revenue of 4.149 billion yuan for Q3 2025, ranking 11th among disclosed peers, which is a decrease of 293 million yuan or 6.59% year-on-year [1] - The net profit attributable to shareholders was 80.7629 million yuan, ranking 22nd among peers, reflecting a decline of 87.5938 million yuan or 52.03% year-on-year [1] - The net cash inflow from operating activities was 537 million yuan, ranking 7th among peers, with an increase of 31.7112 million yuan or 6.28% year-on-year [1] Financial Ratios - The latest debt-to-asset ratio is 18.24%, ranking 11th among peers, down 1.13 percentage points from the previous quarter and down 2.96 percentage points year-on-year [3] - The latest gross profit margin is 52.19%, ranking 26th among peers, with an increase of 0.74 percentage points from the previous quarter but a slight decrease of 0.02 percentage points year-on-year [3] - The latest return on equity (ROE) is 0.93%, ranking 34th among peers, down 0.98 percentage points year-on-year [3] Earnings Per Share and Turnover Ratios - The diluted earnings per share is 0.03 yuan, ranking 32nd among peers, a decrease of 0.03 yuan or 50.00% year-on-year [3] - The latest total asset turnover ratio is 0.38 times, ranking 19th among peers, unchanged from the previous year but down 1.10% year-on-year [3] - The latest inventory turnover ratio is 1.25 times, ranking 26th among peers, with an increase of 0.16 times year-on-year, marking a 14.28% increase [3] Shareholder Structure - The number of shareholders is 96,300, with the top ten shareholders holding 1.3 billion shares, accounting for 43.27% of the total share capital [3] - The largest shareholder is Chengdu Xingcheng Investment Group Co., Ltd., holding 22.24% of the shares [3]